A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals

Last updated: November 17, 2025
Sponsor: Olfactive Biosolutions, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obesity

Hypertriglyceridemia

Diabetes Prevention

Treatment

The Study Product (Pivit)

Clinical Study ID

NCT07245914
PS16
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to observe the impact of Pivit on body weight in overweight individuals. Additionally, the study aims to observe the impact of the product on appetite, hunger, cravings, and general well-being via activities and technologies that can successfully and effectively be completed in a home setting. A consumer-driven, decentralized observational clinical research study is therefore well-suited for examining the impact of this product in this population.

The study team will examine the outcomes in a broad age-range of adults who have chosen to try this product. The study will incorporate participant reported outcome questionnaires and surveys and at-home body weight measurement using a personal scale. There is no "doctor-patient" relationship as part of this research since the participant as a consumer is making the informed choice to take the product and take part in the observational process with self-reported measures and at-home body weight measurement. Findings from this study will contribute knowledge toward the tolerability and formulation of the plant-derived consumer product and the design of future studies.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 years and older

  • Has self-reported body mass index (BMI) between 25 and 34.9 kg/m2.

  • Interested in learning about weight management and appetite and in trying Pivitproduct for themselves.

  • GLP-1 medication naive or has not taken any GLP-1 inducing weight-loss medicationsprior to enrollment.

  • Willingness to refrain from taking any weight loss supplements during the study.

  • Has a personal digital weight scale at home to use during the study.

  • In good general health at the time of screening (Investigator discretion).

  • Able to read and understand English.

  • Able to read, understand, and provide informed consent.

  • Able to use a personal smartphone device and download Chloe by People Science.

  • Able to receive shipment of the product at an address within the United States.

  • Able to complete study assessments over the course of up to 17 weeks.

Exclusion

Exclusion Criteria:

Any potential participants who:

  • Do not have a personal smartphone, internet access, or unwilling to download Chloe.

  • Currently on or planning to start a fad diet, keto diet, pure carnivore diet, rawfood diet, fruitarian diet, liquid diet (does not include vegans or vegetarians)

Concomitant Conditions and Therapies:

  • Any investigational therapies or treatments within 30 days prior to enrollment.

  • GLP-1 receptor agonists and related incretin mimetics, (e.g. semaglutide (Ozempic,Rybelsus), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), sitagliptin (Januvia, Janumet),saxagliptin (Onglyza, Komblglyze), alogliptin (Nesina, Kazano, Oseni), linagliptin (Tradjenta, Jentadueto) or tirzepatide (Mounjaro)

  • Currently diagnosed with Alcohol Use Disorder and/or Substance Use Disorder

  • Currently pregnant, planning to become pregnant in the next 1 month, orbreastfeeding

  • Any underlying medical conditions or comorbidities that may confound the evaluationof the study outcomes.

  • Have a significant illness, disease or condition which, in the opinion of theprincipal investigator, may impact their ability to participate in the study orimpact the study outcomes.

  • Known hypersensitivity or previous allergic reaction to Cinnamaldehyde, SpearmintOil, Eugenol, Butyl butyryl lactate, Benzyl acetate, Lauric acid, Sodium-CopperChlorophyllin, Sunflower Seed Oil, Gelatin, Glycerin

  • Are unlikely for any reason to be able to comply with the trial or consideredunsuited for participation in the study by the Principal Investigator.

Study Design

Total Participants: 125
Treatment Group(s): 1
Primary Treatment: The Study Product (Pivit)
Phase:
Study Start date:
July 30, 2025
Estimated Completion Date:
February 24, 2026

Study Description

Pivit is a proprietary and patented formulation of food molecules, designed to act on receptors in the gut to cause a natural secretion of GLP-1 and GIP hormones. GLP-1 and GIP are hormones that naturally delay stomach emptying to reduce appetite and trigger the pancreas to secrete insulin which regulates blood sugar. Pivit has been shown to naturally increase GLP-1 and GIP in human cellular studies and in initial consumer trials, which in turn increase feelings of satiety and lessen hunger pangs, lower blood sugar and support healthy insulin sensitivity. Pivit may also lessen interest in alcohol and reduce 'food noise,' thoughts about food throughout the day and curtail the urge to snack.

Connect with a study center

  • People Science

    Los Angeles 5368361, California 5332921 90034
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.